Ruxolitinib (RUX) cream is well tolerated with potent anti-inflammatory and antipruritic efficacy for the treatment of atopic dermatitis (AD), according to a recent study published in the Journal of the American Academy of Dermatology.
Researchers aimed to evaluate the 8-week efficacy and safety of RUX cream in patients with AD in two phase 3 studies. TRuE-AD1 and TRuE-AD2 enrolled patients aged 12 years or older with AD for 2 or more years, an Investigator Global Assessment score of 2 or 3, and 3% to 20% affected body surface area. Randomized patients received either twice-daily 0.75% RUX cream, 1.5% RUX cream, or vehicle cream for 8 continuous weeks.
More patients experienced treatment success with 0.75% and 1.5% RUX cream vs vehicle at week 8 and itch reductions were reported within 12 hours of first application of 1.5% RUX cream compared with vehicle. No significant application site reactions were reported with RUX cream.
“RUX cream showed anti-inflammatory and prompt antipruritic effects with superior efficacy versus vehicle and was well tolerated,” concluded the study authors. –Lisa Kuhns
Reference
Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from two phase 3, randomized, double-blind studies. J Am Acad Dermatol. Published online May 3, 2021. doi:10.1016/j.jaad.2021.04.085
